明视
中间视觉
角膜塑形术
眼科
小学生
睫状肌麻痹
眼睛畸变
泽尼克多项式
数学
医学
瞳孔直径
折射误差
验光服务
角膜
光学
视网膜
物理
眼病
视力
波前
作者
Stephen J. Vincent,Qi Tan,Alex L. K. Ng,George P. M. Cheng,Victor C P Woo,Pauline Cho
摘要
Abstract Purpose To compare the changes in higher order aberrations (HOA’s) for photopic and mesopic pupil diameters in children undergoing orthokeratology treatment (OK) or combined 0.01% atropine with orthokeratology treatment (AOK), and their association with axial elongation. Methods Children aged 6 to <11 years with 1.00–4.00 D of myopia were randomly assigned to each treatment group. Photopic and mesopic pupil diameters were quantified using automated pupillometry and HOA’s were measured with a Hartmann‐Shack aberrometer and Badal system to control for accommodation. HOA’s were rescaled to photopic and mesopic pupil diameters and fitted with a 6 th order Zernike polynomial expansion. Axial length was measured using an optical biometer under cycloplegia. Results Baseline and six‐month data from 25 AOK and 28 OK participants were analysed. At the six‐month visit, pupil diameter was larger in the AOK group under photopic conditions (3.70 ± 0.42 vs 3.12 ± 0.33 mm, p < 0.001), along with a range of HOA metrics [3 rd to 6 th order and higher order root mean square error values (HO RMS), all p ≤ 0.003] and individual Zernike terms (primary spherical aberration, and oblique quadrafoil, both p ≤ 0.03). Axial elongation was greater in the OK treatment group (0.05 ± 0.08 vs −0.01 ± 0.12 mm, p = 0.02). In the AOK group, axial elongation was correlated with the increase in photopic pupil diameter ( r = −0.45, p = 0.02) and with several HOA metrics; however, these associations were not observed in the OK group. Conclusion AOK treatment resulted in increased photopic pupil size and HOA’s, and significantly less axial elongation over a six‐month period compared to OK treatment alone. The improved myopia control observed with combination 0.01% atropine and orthokeratology may be a result of an enhanced optical effect due to a larger photopic pupil size.
科研通智能强力驱动
Strongly Powered by AbleSci AI